Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 920 | 165 | 734 |
| Samples | 816 | 139 | 662 |
| Peptides | 673 | 101 | 576 |
Function
ARHGAP35 · Rho GTPase activating protein 35
The human glucocorticoid receptor DNA binding factor, which associates with the promoter region of the glucocorticoid receptor gene (hGR gene), is a repressor of glucocorticoid receptor transcription. The amino acid sequence deduced from the cDNA sequences show the presence of three sequence motifs characteristic of a zinc finger and one motif suggestive of a leucine zipper in which 1 cysteine is found instead of all leucines. The GRLF1 enhances the homologous down-regulation of wild-type hGR gene expression. Biochemical analysis suggests that GRLF1 interaction is sequence specific and that transcriptional efficacy of GRLF1 is regulated through its interaction with specific sequence motif. The level of expression is regulated by glucocorticoids. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000672722 | Q9NRY4 | 920 | 673 |
Gene Properties
Recurrent Mutations
All 673 amino-acid changes on canonical ENST00000672722 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ARHGAP35 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ARHGAP35 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 9/40 22% | 0/0 0% |
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| Endometrial Carcinoma | 11/42 26% | 47/612 8% |
| Hodgkins Lymphoma | 2/16 12% | 5/122 4% |
| Melanoma | 6/210 3% | 78/1899 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Retinoblastoma | 1/27 4% | 1/30 3% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 23/810 3% |
| Colorectal Carcinoma | 18/143 13% | 87/3239 3% |
| Bladder Carcinoma | 0/58 0% | 30/956 3% |
| Cervical Carcinoma | 0/35 0% | 12/422 3% |
| Unknown | 0/10 0% | 1/29 3% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 37/1390 3% |
| Small Cell Lung Carcinoma | 0/9 0% | 17/752 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Burkitts Lymphoma | 0/32 0% | 5/196 3% |
| Other Solid Cancers | 4/94 4% | 31/1515 2% |
| Gastric Carcinoma | 1/74 1% | 38/1809 2% |
| Neuroendocrine Tumour | 8/154 5% | 7/577 1% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Hepatocellular Carcinoma | 5/46 11% | 35/2210 2% |
| Mesothelioma | 3/62 5% | 1/165 1% |
| Ovarian Carcinoma | 6/109 6% | 12/998 1% |
| Head and Neck Carcinoma | 2/85 2% | 23/1574 1% |
| Other Sarcomas | 3/69 4% | 8/699 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 32/2550 1% |
| Glioma | 1/52 2% | 24/2127 1% |
| Breast Carcinoma | 7/144 5% | 29/3264 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Biliary Tract Carcinoma | 1/54 2% | 9/950 1% |
Mutation Distribution
Where ARHGAP35 is mutated · all tissues, split by cell line vs tissue
How many mutations in ARHGAP35 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 920 mutations in ARHGAP35
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|